Our body's own defense system not only clears away bacteria and viruses, it can also fight cancer. However, not all tumor ...

While mRNA vaccines represent a transformative platform for infectious disease control, their efficacy in antigen-presenting cells (APCs) remains vulnerable to endogenous regulatory networks, ...

Discover a study where researchers have discovered a myeloid-derived antigen-presenting cells population essential for peripherally induced regulatory T cells.

Panelists discuss how chronic graft-vs-host disease (cGVHD) results from complex biological mechanisms involving inflammation, loss of peripheral tolerance, and fibrotic pathways affecting multiple ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

New hope: MHH researchers are mobilising the immune system's defence against tumour cells within just two weeks using a two-phase vaccination regimen.

Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through its proprietary fascin inhibitor technology, today ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

AffyImmune Therapeutics, Inc ., a clinical-stage biopharmaceutical company, today announced an abstract detailing its affinity-tuned CAR T therapy AIC100 will be presented at the ...